



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

7590 05/02/2011
THE LAW OFFICE OF KENNETH K. SHARPLES
Sena Plaza Building
Suite 54
125 East Palace Avenue
Santa Fe, NM 87501

EXAMINER

LUNDGREN, JEFFREY S

ART UNIT

PAPER NUMBER

1629

DATE MAILED: 05/02/2011

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/856,907

05/29/2001

Andrew Raymon Morton Bradbury

DSP/HB/07.01US

6402

TITLE OF INVENTION: LIBRARIES AND USES THEREOF

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$0	\$0	\$1510	08/02/2011

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

7590 05/02/2011

THE LAW OFFICE OF KENNETH K. SHARPLES
Sena Plaza Building
Suite 54
125 East Palace Avenue
Santa Fe, NM 87501

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/856,907	05/29/2001	Andrew Raymon Morton Bradbury	DSP/HB/07.01US	6402
------------	------------	-------------------------------	----------------	------

TITLE OF INVENTION: LIBRARIES AND USES THEREOF

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
-------------	--------------	---------------	---------------------	----------------------	------------------	----------

nonprovisional	NO	\$1510	\$0	\$0	\$1510	08/02/2011
----------------	----	--------	-----	-----	--------	------------

EXAMINER	ART UNIT	CLASS-SUBCLASS
----------	----------	----------------

LUNDGREN, JEFFREY S	1629	506-023000
---------------------	------	------------

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____
- (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____
- 3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
- ☐ Publication Fee (No small entity discount permitted)
- ☐ Advance Order - # of Copies _____

4b. Payment of Fee(s); (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/856,907	05/29/2001	Andrew Raymon Morton Bradbury	DSP/HB/07.01US	6402

7590 05/02/2011
THE LAW OFFICE OF KENNETH K. SHARPLES
Sena Plaza Building
Suite 54
125 East Palace Avenue
Santa Fe, NM 87501

EXAMINER

LUNDGREN, JEFFREY S

ART UNIT	PAPER NUMBER
----------	--------------

1629

DATE MAILED: 05/02/2011

Determination of Patent Term Extension under 35 U.S.C. 154 (b)

(application filed after June 7, 1995 but prior to May 29, 2000)

The Patent Term Extension is 0 day(s). Any patent to issue from the above-identified application will include an indication of the 0 day extension on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No.	Applicant(s)	
	09/856,907	BRADBURY ET AL.	
	Examiner	Art Unit	
	JEFFREY S. LUNDGREN	1629	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the reply of October 13, 2010.
2. ☒ The allowed claim(s) is/are 1,2,4-44,46 and 75.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date ____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| <ol style="list-style-type: none"> 1. <input type="checkbox"/> Notice of References Cited (PTO-892) 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3. <input type="checkbox"/> Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date ____ 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | <ol style="list-style-type: none"> 5. <input type="checkbox"/> Notice of Informal Patent Application 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date ____. 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance 9. <input type="checkbox"/> Other ____. |
|--|---|

/Jeffrey S. Lundgren/
 Supervisory Patent Examiner, Art Unit 1629

Art Unit: 1629

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ken Sharples on February 8, 2011.

The claims below represent the complete listing of claims.

1. (Previously Presented) A method of preparing a nucleic acid library, said method comprising introducing at least two members of an initial population of nucleic acid molecules into at least one cell, wherein members of the initial population of nucleic acid molecules comprise two sequence segments,
 - (a) wherein all first sequence segments are identical and include at least one origin of replication; and,
 - (b) wherein the second sequence segment comprises a library of diverse expression sequences, wherein each of the diverse expression sequences in the library is different and comprises at least one substrate for recombination,such that recombination of the substrate occurs between at least two members of the initial population of nucleic acid molecules, thereby producing a population of nucleic acid molecules comprising recombined nucleic acid members.
2. (Original) The method of claim 1, wherein said recombination is performed by a recombination mechanism endogenous to said cell.
3. (Cancelled)
4. (Original) The method of claim 1, wherein said recombination is mediated by

Art Unit: 1629

an endogenous recombinase.

5. (Original) The method of claim 1, wherein said recombination is at a site preselected for recombination.

6. (Original) The method of claim 5, wherein the site preselected for recombination is a recombinase recognition site and the recombination is mediated by a recombinase expressed by said cell.

7. (Original) The method of claim I, wherein said recombination is mediated by a recombinase selected from the group consisting of a member of the hin family of recombinase, a member of the lambda integrase family, an flp recombinase, a resolvase, a transposon, and a Cre recombinase.

8. (Original) The method of claim 7, wherein said recombinase is selected from the group consisting of Cre, hin, gin, pin, cin, and flp.

9. (Original) The method of claim 5, wherein said site preselected for recombination is a LoxP site.

10. (Previously Presented) The method of claim 1, wherein said substrate for recombination comprises:

- (i) a first site recombinase recognition site; and,
- (ii) a second recombinase recognition site different from the first recombinase recognition site.

11. (Original) The method of claim 10, wherein recombination results in the exchange, between two members of said nucleic acid population, of the nucleic acid flanked by the first and second recombinase recognition sites.

Art Unit: 1629

12. (Original) The method of claim 10, wherein the first recombinase recognition site is a loxP site and the second recombinase recognition site is loxP mutant site.

13. (Original) The method of claim 12, wherein the IQXP mutant site is loxP 511.

14. (Original) The method of claim 1, wherein said cell is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell, and a mammalian cell.

15. (Original) The method of claim 14, wherein said bacterial cell is an Escherichia coli cell.

18. (Original) The method of claim 1, wherein said members of a population of nucleic acid molecules are introduced into the cell by transfection.

17. (Original) The method of claim i, wherein said population of nucleic acid molecules comprises at least 10 different members.

18. (Original) The method of claim 1, wherein said members of a population of nucleic acid molecules are contained within infectious particles and are introduced into the cells via infection with said infectious particles.

19. (Original) The method of claim 18, wherein said infectious particles are phage.

20. (Original) The method of claim 19, wherein said infectious particles are filamentous phage.

21. (Original) The method of claim 20, wherein the infectious particles are filamentous phage of the Ff family.

22. (Original) The method of claim 18, wherein said infectious particles are phagemids containing phagemidic DNA.

Art Unit: 1629

23. (Original) The method of claim 18, wherein said infectious particles are phagemids derived from filamentous phage of the Ff family.

24. (Original) The method of claim 1, wherein said method further comprises:
transfecting or infecting one or more cells with members of said population of recombined nucleic acid members such that said cells are infected at a multiplicity of infection (moi) of less than about 1.

25. (Original) The method of claim 24, wherein said further method comprises the packaging of members of said nucleic acid library in replicable genetic display packages such that a protein on the surface of the replicable display package is encoded by a nucleic acid packaged within the display package that is a nucleic acid sequence that varies between members of the nucleic acid library.

26. (Original) The method of claim I, wherein the variable nucleic acid sequence comprising the substrate for recombination comprises an expression cassette.

27. (Original) The method of claim 26, wherein said expression cassette comprises nucleic acid sequences encoding one or more polypeptides.

28. (Original) The method of claim 26, wherein said expression cassette comprises nucleic acid sequences- encoding one or more polypeptides and the nucleic acid encoding at least one of said polypeptides is flanked by pair of recombinase recognition sites.

29. (Original) The method of claim 27, wherein said polypeptides are expressed on the surface of a phage, a phagemid, or a bacterium.

30. (Original) The method of claim 27, wherein said variable sequence includes nucleic acid encoding a first polypeptide chain and a second polypeptide chain from a specific binding pair

Art Unit: 1629

member such that following recombination said variable sequence encodes binding proteins that: are not present in the initial population of nucleic acids.

31. (Original) The method of claim 30, wherein said first and said second polypeptide are antibody polypeptides.

32. (Original) The method of claim 31, wherein said first and second polypeptide are selected from the group consisting of a V_H region, a V_L region, a V_H CDR1, a V_H CDR2, a V_H CDR3, a V_L CDR1, a V_L CDR2, a V_L CDR3, a V_H joined to a C_H1 , and a V_L joined to a C_L .

33. (Original) The method of claim 32, wherein the first polypeptide is a V_H region and the second polypeptide is a V_L region.

34. (Previously Presented) The method of claim 30, wherein

- (i) a pair of recombinase recognition sites flank the nucleic acid encoding a first polypeptide; and
- (ii) said pair of recombinase recognition sites comprise a first recombinase recognition site and a different second recombinase recognition site.

35. (Original) The method of claim 34, wherein the first recombinase recognition site is a LoxP site, and the second recombinase recognition site is a LoxP 511 site.

36. (Original) The method of claim 30, wherein the first polypeptide is flanked by a pair of recombinase recognition sites and the recognition sites are different from each other.

37. (Previously Presented) The method of claim 30, wherein (i) the first polypeptide and the second polypeptide are each flanked by a pair of recombinase recognition sites; and, (if) the recognition sites within each pair are different from each other.

Art Unit: 1629

38. (Original) The method of claim 36, wherein said loxP sites are selected from the group consisting of loxP, loxP 511, and fas loxP.

39. (Original) The method of claim 29, wherein the members of said library encode a single-chain antibody.

40. (Original) The method of claim 39, in which said antibody fragments are scFv.

41. (Original) The method of claim 29, wherein the members of said library encode a moiety selected from the group consisting of a Fab, an Fv, antibody, a V_H dimer, and a V_L dimer.

42. (Original) The method of claim 29, wherein the members of said library encode an antibody in which the antibody V regions are linked by a polypeptide linker comprising a recombinase recognition site.

43. (Previously Presented) The method of claim 42, wherein said recombinase recognition site is selected from the group consisting of loxP, a loxP mutant, a recognition site for a hin family recombinase, a recognition site for a lambda integrase, a recognition site for an flp recombinase, a recognition site for a resolvase, and a recognition site for a transposon.

44. (Previously Presented) A method according to claim 1, wherein the second sequence segment further comprises a selectable marker whereby said selectable marker must be recombined with a second selectable marker to become active.

45. (Cancelled)

46. (Original) The method of claim 44 wherein said selectable marker is inactive without recombination because it is an incomplete selectable marker.

Art Unit: 1629

47. (Original) The method of claim 44 wherein said selectable marker is located such that it is linked to the recombination substrate and co-transferred with a gene of interest in said recombination substrate.

48 - 92. (Cancelled).

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

Johnson, nor any other art of record, does not teach or fairly suggest the instantly claimed method set forth in Applicants' claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusions

If Applicants should amend the claims, a complete and responsive reply will clearly identify where support can be found in the disclosure for each amendment. Applicants should point to the page and line numbers of the application corresponding to each amendment, and provide any statements that might help to identify support for the claimed invention (e.g., if the amendment is not supported in *ipsis verbis*, clarification on the record may be helpful). Should Applicants present new claims, Applicants should clearly identify where support can be found in the disclosure.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeff Lundgren whose telephone number is 571-272-5541. The Examiner can normally be reached from 7:00 AM to 5:30 PM.

Art Unit: 1629

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Jeffrey S. Lundgren/

Supervisory Patent Examiner, Art Unit 1629